Can you take weight loss injections with Crohn's disease?

You've been told these injections cause stomach problems. You already have them.

That concern comes up often. A question our prescribers hear most weeks is some version of: "I've got Crohn's, are these injections going to make everything worse?" It is a fair and sensible thing to ask.

GLP-1 receptor agonists like tirzepatide (Mounjaro) and semaglutide (Wegovy) reduce appetite partly by slowing how quickly the stomach empties. That mechanism is helpful for weight management, but it also produces the side effects the medicines are known for: nausea, loose stools, vomiting, bloating and cramping. Those effects are usually most pronounced in the first few weeks of treatment and tend to settle as the body adjusts. For most people without pre-existing GI conditions, they are manageable.

For someone with Crohn's disease, the picture is more complicated. The side effect profile of GLP-1 medicines overlaps directly with Crohn's symptoms. Starting a medicine that can trigger loose stools and abdominal discomfort when your gut is already inflamed, or when you are in the middle of a flare, creates a genuine monitoring challenge, it becomes harder to separate a drug side effect from disease activity. That is not a reason to rule treatment out entirely, but it is exactly why a prescriber needs the full picture before approving anything. You can read more about how Crohn's disease interacts with weight loss injections in our detailed overview.

The good news is that stable, well-controlled Crohn's disease looks quite different clinically from an active flare, and the prescribing conversation starts there.

What the prescribing information actually says about inflammatory bowel disease

Neither the tirzepatide nor the semaglutide Summary of Product Characteristics lists Crohn's disease as an absolute contraindication. However, both medicines carry warnings around gastrointestinal disease more broadly, and the clinical expectation is that prescribers exercise judgment for patients with significant GI conditions. The standard guidance on the NHS tirzepatide medicines page flags that anyone with a history of serious GI problems should discuss this with their doctor or pharmacist before starting.

In practice, the relevant considerations include: whether your Crohn's is currently in remission or active; whether you have had bowel resections or strictures that could affect how the medicine behaves; whether you are taking immunosuppressants or biologics that carry their own interaction considerations; and whether you have a history of complications like fistulas or abscesses that make GI disturbance riskier than average.

The January 2026 MHRA Drug Safety Update is also relevant here. It reinforced that acute pancreatitis (severe, persistent stomach pain that may radiate to the back) is a known, infrequent but serious side effect of GLP-1 medicines. If you already have abdominal symptoms from Crohn's, knowing what pancreatitis warning signs look like matters, and any prescriber reviewing your case should walk you through them. You can report any suspected side effects via the MHRA Yellow Card scheme.

Weight and Crohn's disease have a complicated relationship too. Malabsorption, restricted diets and flare-related appetite loss mean some people with Crohn's are underweight rather than overweight, while others gain weight on long-term steroid use or during remission. A prescriber assessing eligibility will look at your BMI in the context of your condition history, not just the number itself. For a broader look at what affects eligibility for these medicines, our weight loss injections guide covers the licensed criteria in full.

Active flare versus stable remission: why timing matters

This distinction is probably the most practically important thing to understand. Starting a GLP-1 medicine during an active Crohn's flare is generally considered poor timing by most prescribers, for two reasons. First, any additional GI burden during a flare risks worsening dehydration and discomfort at a time when the gut is already under stress. Second, if symptoms worsen after starting the injection, neither you nor your clinical team can easily tell whether that is the medicine or the disease.

In stable remission, the risk-benefit calculation shifts. GI side effects from GLP-1 medicines can still occur, but they are more distinguishable from baseline and more likely to be manageable with the slow titration schedules that both tirzepatide and semaglutide use. The starting doses (tirzepatide begins at 2.5mg, for instance) exist specifically to give the body time to adjust before any increase.

There is also emerging interest in the scientific literature around GLP-1 receptors and gut inflammation, though this remains early-stage research and should not be read as evidence that these medicines treat Crohn's. Weight management itself, however, is a legitimate therapeutic goal for many people with Crohn's, and achieving a healthier weight can reduce the load on joints and improve cardiovascular markers that steroids and long-term inflammation can affect. If you are curious how safety considerations specific to Crohn's are weighed up, our page on weight loss injections and Crohn's walks through the key factors in detail. People with other chronic conditions sometimes ask similar questions; our page on weight loss injections and heart disease shows how these assessments work for complex presentations more broadly.

If you are considering treatment and your Crohn's is currently well-controlled, the right next step is a detailed clinical consultation, one where your full GI history, current medicines and recent disease activity can all be assessed properly. Our overview of weight loss injection options explains what that consultation covers at nume. Treatment pricing and what is included in the service are set out on our treatment page.

What to bring to a consultation if you have Crohn's disease

Being prepared makes the clinical review faster and more useful. A prescriber assessing your suitability for a GLP-1 medicine alongside Crohn's will want to know: your current disease status (in remission, or actively flaring); your most recent inflammatory markers if you have them; any surgical history affecting the bowel; your current medication list, including any biologics, immunosuppressants or steroids; and whether you have any complications such as strictures or fistulas that would affect GI tolerance.

You do not need a letter from your gastroenterologist to start a consultation, but if your Crohn's management is led by a specialist, it is worth letting them know you are considering weight management medication. Joined-up care is better care, and the MHRA and NHS both expect prescribers to notify your GP of treatment, which is standard practice at nume.

People with other organ-related considerations sometimes ask parallel questions; the page on weight loss injections and kidney disease shows how we approach similarly complex cases. If you are ready to have your situation reviewed by a GPhC-registered prescriber, you can start your free consultation below.